title: Psychiatric aspects of phosphodiesterases: An overview.
abstract: Phosphodiesterases (PDE) are exciting new targets in medical sciences. These enzymes are some of the key mediators of cellular functions in the body and hence are attractive sites for drug-induced modulations. With the finding that Tofisopam, a new anxiolytic, inhibits PDEs, the authors were inspired to look into the role of PDE and drugs acting on them in psychiatry. Hence, the review was undertaken. We found several research materials available highlighting the role of PDE in cellular functions and the possible newer etiological mechanisms of neuropsychiatric illnesses such as schizophrenia, depression/anxiety disorders, and cognitive dysfunction involving PDEs. We also found that there are many molecules acting on PDEs, which have the potential to alter the way we treat mental illnesses today. This article is intended to provide an in-depth look at these enzymes so that more cost-effective therapeutic molecules may be synthesized and marketed in India for managing mental illnesses.
authors.affiliation: Department of Psychiatry, Krishna Institute of Medical Sciences Deemed University, Karad, Satara, Maharashtra, India.
authors.forename: Vasantmeghna S
authors.initials: VS
authors.lastname: Murthy
authors.affiliation: Department of Psychiatry, Krishna Institute of Medical Sciences Deemed University, Karad, Satara, Maharashtra, India.
authors.forename: Ajish G
authors.initials: AG
authors.lastname: Mangot
mesh_terms: D000818:Animals; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D000928:Antidepressive Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001007:Anxiety / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D001569:Benzodiazepines / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D003072:Cognition Disorders / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D003863:Depression / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism; D006801:Humans; D007527:Isoenzymes / Q000037:antagonists & inhibitors / Q000378:metabolism; D001523:Mental Disorders / Q000188:drug therapy* / Q000201:enzymology / Q000378:metabolism; D008959:Models, Neurological; D058990:Molecular Targeted Therapy / Q000009:adverse effects; D009419:Nerve Tissue Proteins / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009474:Neurons / Q000187:drug effects* / Q000201:enzymology / Q000378:metabolism; D018697:Nootropic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D010726:Phosphodiesterase Inhibitors / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D010727:Phosphoric Diester Hydrolases / Q000737:chemistry / Q000378:metabolism*; D012559:Schizophrenia / Q000188:drug therapy / Q000201:enzymology / Q000378:metabolism
chemical_list: D014151:Anti-Anxiety Agents; D000928:Antidepressive Agents; D014150:Antipsychotic Agents; D007527:Isoenzymes; D009419:Nerve Tissue Proteins; D018697:Nootropic Agents; D010726:Phosphodiesterase Inhibitors; D001569:Benzodiazepines; D010727:Phosphoric Diester Hydrolases; C012582:tofisopam
keywords: Affective disorders; anxiety; cognition; phosphodiesterase; phosphodiesterase inhibitor; schizophrenia